This review concluded that atypical antipsychotics were effective augmentation agents in major depressive disorder, but were associated with an increased risk of discontinuation due to adverse events. Given some shortcomings in the review process, small sample sizes of a number of trials and the uncertain quality of the included trials, the authors' conclusions should be interpreted with caution.
Study selection
Double-blind randomised controlled trials (RCTs) that compared adjunctive atypical antipsychotic agents with placebo in patients with non-psychotic unipolar major depressive disorder were eligible for inclusion. Patients had to have nonpsychotic major depressive disorder that was resistant to prior antidepressant treatment determined by either history or a prospective trial. Outcomes included response (defined as an improvement of at least 50% from baseline to endpoint on either the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale), remission and rates of discontinuation.
In the included trials, atypical antipsychotic agents comprised olanzapine, risperidone, quetiapine, and aripiprazole. Antidepressants included fluoxetine, various agents and serotonin re-uptake inhibitors/serotonin noradrenaline reuptake inhibitors. Duration of the included trials ranged from four to 12 weeks; nearly all were between six and eight weeks.
